SCHEMBL106530

SCHEMBL106530

COc1cc(C(C)(C)C)ccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
NR1H4 Q96RI1 3/20 0.56
TDP1 Q9NUW8 2/20 0.53
KDM4E B2RXH2 4/20 0.51
HPGD P15428 4/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
CYP2C19 P33261 1/20 0.51
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
PPARG P37231 3/20 0.48
PPARA Q07869 3/20 0.48
MAPT P10636 3/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
RXRB P28702 1/20 0.45
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
LMNA P02545 1/20 0.44
NPY1R P25929 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10519686 0.89 ALDH1A1 (0.59) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL17908094 0.88 ALDH1A1 (0.57) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL690558 0.86 NR1H4 (0.53) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL3620853 0.86 NR1H4 (0.56) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL9187252 0.84 NR1H4 (0.52) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL422034 0.84 ALDH1A1 (0.71) ALDH1A1TDP1KDM4EHPGDHSD17B10
SCHEMBL1860562 0.84 TDP1 (0.51) ALDH1A1NR1H4TDP1KDM4EHPGD
SCHEMBL12244969 0.84 MAPT (0.56) ALDH1A1NR1H4KDM4EHPGDHSD17B10
SCHEMBL10212180 0.84 NR1H4 (0.51) ALDH1A1NR1H4KDM4EHPGDMAPT
SCHEMBL107111 0.84 NR1H4 (0.51) ALDH1A1NR1H4TDP1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors SMITHKLINE BEECHAM CORPORATION 2004-02-05 US claimed
US-20230265055-A1 STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS OXFORD FINANCE LLC 2023-08-24 US disclosed
US-20200172473-A1 DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN (DE) 2020-06-04 US disclosed
CN-110891560-A Dual modulators of farnesoid X receptor and soluble epoxide hydrolase 法兰克福大学 2020-03-17 CN disclosed
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-01-29 US disclosed
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-07-12 US disclosed
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-07-12 US disclosed
US-9920056-B2 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives ELI LILLY AND COMPANY (US) 2018-03-20 US disclosed
US-9884043-B2 RORgammaT inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 US disclosed
US-9884043-B2 RORgammaT inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 US disclosed
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
EP-1102769-A2 TRICYCLIC CARBOXAMIDES SMITHKLINE BEECHAM PLC (GB) 2001-05-30 EP disclosed
WO-2001002366-A2 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-01-11 WO disclosed
US-6110934-A Substituted benzamide derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2000-08-29 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-2000008020-A2 TRICYCLIC CARBOXAMIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-17 WO disclosed
WO-1999052857-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1999-10-21 WO disclosed
EP-0944598-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-09-29 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed
WO-1998024764-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM P.L.C. (GB) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors APOB, APOL1, CETP ALDH1A1 4110/4885NR1H4 351/4885TDP1 1712/4885
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 ALDH1A1 4309/4885NR1H4 993/4885TDP1 898/4885
US-20200172473-A1 DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE NR1H4, NR1H3, NR1H2 ALDH1A1 983/4885NR1H4 1/4885TDP1 4578/4885
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS BET1, PGGT1B, RABGGTB ALDH1A1 2319/4885NR1H4 1009/4885TDP1 2918/4885
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ALDH1A1 494/4885NR1H4 1052/4885TDP1 2520/4885
US-20230265055-A1 STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS STAT5B, STAT5A, STAT3 ALDH1A1 3726/4885NR1H4 1499/4885TDP1 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.